ClinicalTrials.gg
RecruitingNCT07402018Updated Feb 11, 2026

Intra-aortic Balloon Counterpulsation (IABC) Compliance

An observational study in Cardiogenic Shock, IABC Procedure and Intraaortic Balloon Counterpulsation (IABC), sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Thomas Jefferson University · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 50 studies in Shock, Cardiogenic with a site in United States — 19 open to participants now, 23 under way, none of them phase 3. Shock, Cardiogenic · United States.

Planned enrollment
21st of 25
20 · median 124
Started
2026
with 4 others
Observational
25 of 50
9 open now
Primary completion
2026-12
later than 1 of 22 live
Registered
46th of 50
by date

Among the 50 studies in Shock, Cardiogenic with a site in United States, this one is the 21st largest by planned enrollment of the 25 observational ones that give a count, is one of 5 that started in 2026, is one of 25 observational ones, reaches primary completion later than 1 of the 22 other live ones, and was the 46th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

19 of the 50 studies in Shock, Cardiogenic with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Shock, Cardiogenic with a site in United States, or all of them as a file.
02

Study summary

The investigators intend to study how baseline arterial compliance (as defined by stroke volume/pulse pressure) influences the clinical success of intraaortic balloon counterpulsation (IABC) in patients with cardiogenic shock (CS). The investigators aim to compare clinical outcomes in CS patients requiring IABC with normal compliance versus low compliance. The study will enroll patients undergoing IABC that are clinically indicated. Baseline hemodynamic measurements will be obtained and then patients would be stratified based on their compliance. Post IABC, serial hemodynamic measurements will be obtained and compared between groups. Patients will continue to be followed longitudinally until the IABC has been discontinued for any reason. The proposed study will yield results that will aid in developing a larger clinical trial and ultimately assist clinicians in determining if IABC is appropriate therapy for patients in cardiogenic shock.

Read the detailed description

This study will focus on patients in cardiogenic shock (CS) that will be undergoing clinically indicated intraaortic balloon counterpulsation (IABC) insertion and right heart catheterization. Prior to IABC insertion a patient will have their clinically indicated right heart catheterization. The investigators will record these baseline hemodynamic parameters, including (but not limited to) stroke volume and arterial pulse pressure.

After IABC insertion is completed, repeat hemodynamic measurements will be obtained approximately 30 minutes later. Repeat hemodynamic measurements will be recorded at approximately 3-6 hours following the procedure, and 24 hours following the procedure. The act of recording hemodynamic measurements is part of the usual clinical management of patients with IABC.

The patients will continue be followed longitudinally until their IABC course has completed, either due to resolution of CS, exchange for a separate device, heart transplantation, durable Left Ventricular Assist Device (LVAD) implant, or patient death.

The investigators hypothesize that patients with low arterial compliance will have greater improvements in cardiac output and cardiac filling pressures compared to patients with normal compliance. The specific aims are to (1) compare hemodynamic changes with IABC in cardiogenic shock patients with low compliance vs those with normal compliance and (2) to determine a cutoff value of compliance that can be used for future larger clinical trials.

The proposed study will yield results that will aid in developing a larger clinical trial and ultimately assist clinicians in determining if IABC is appropriate therapy for patients in cardiogenic shock.

03

Conditions studied

  • Cardiogenic Shock
  • IABC Procedure
  • Intraaortic Balloon Counterpulsation (IABC)

Browse trials for

Keywords

  • Cardiogenic shock
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cardiogenic shock patients undergoing Intra-aortic Balloon Counterpulsation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old
  • Cardiogenic shock
  • Undergoing Intra-aortic Balloon Counterpulsation (IABC) as part of clinical care
  • Able to provide consent or have power of attorney or next of kin provide consent

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years old
  • Unable to consent or does not have power of attorney or next of kin to consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Cardiac Output (L/min)

    Time frame: 24 hours

Secondary outcomes

  1. Systolic Blood Pressure (mmHg)

    Time frame: 30 minutes

  2. Pulmonary Artery Oxygen Saturation (%)

    Time frame: 24 hours

  3. Ultimate Disposition

    Hospital death

    Time frame: Longitudinal Follow-Up (approximately 3 months)

  4. Total Bilirubin (mg/dL)

    participant laboratory value

    Time frame: 24 hours

  5. ALT (U/L)

    participant laboratory value

    Time frame: 24 hours

  6. AST (U/L)

    participant laboratory value

    Time frame: 24 hours

  7. Creatine Clearance/GFR

    Time frame: 24 hours

  8. Creatine (mg/dL)

    participant laboratory value

    Time frame: 24 hours

  9. Lactate millimoles per liter (mmol/L)

    participant laboratory value

    Time frame: 24 hours

  10. Pulmonary Artery Compliance (mmHg)

    Time frame: 24 hours

  11. Right Ventricular Stroke Work Index (g·m-²·beat-¹)

    Time frame: 24 hours

  12. Pulmonary Artery Pulsatility Index (PAPi)

    calculated measurement

    Time frame: 24 hours

  13. Pulmonary Vascular Resistance (dynes/cm⁵)

    Time frame: 24 hours

  14. Systemic Vascular Resistance (mmHg/L/min)

    Time frame: 24 hours

  15. Pulmonary Capillary Wedge Pressure (mmHg)

    Time frame: 24 hours

  16. Diastolic Pulmonary Arterial Pressure (mmHg)

    Time frame: 24 hours

  17. Systolic Pulmonary Artery Pressure (mmHg)

    Time frame: 24 hours

  18. Right Atrium Pressure (mmHg)

    report measurement

    Time frame: 24 hours

  19. Aortic Pulsatility Index (API)

    calculated measurement

    Time frame: 24 hours

  20. Cardiac Power Input (W/m²)

    Time frame: 24 hours

  21. Cardiac Power Output (Watts)

    Time frame: 24 hours

  22. Stroke Volume (mL)

    Time frame: 24 hours

  23. Cardiac Index (L/min/m²)

    Time frame: 24 hours

  24. Heart Rhythm

    Normal Sinus Rhythm, Atrial Fibrillation, Atrial Flutter, Ventricular Fibrillation, Ventricular Tachycardia, Sinus Bradycardia, Sinus Tachycardia, other

    Time frame: 24 hours

  25. Heart Rate (beats per minute)

    Time frame: 24 hours

  26. Mean Arterial Pressure (mmHg)

    Time frame: 24 hours

  27. Diastolic Blood Pressure (mmHg)

    Time frame: 24 hours

  28. Systolic Blood Pressure (mmHg)

    Time frame: 24 hours

  29. Pulmonary Artery Compliance (mmHg)

    Time frame: 3-6 hours

  30. Right Ventricular Stroke Work Index (g·m-²·beat-¹)

    Time frame: 3-6 hours

  31. Pulmonary Artery Pulsatility Index (PAPi)

    calculated measurement

    Time frame: 3-6 hours

  32. Pulmonary Vascular Resistance (dynes/cm⁵)

    Time frame: 3-6 hours

  33. Systemic Vascular Resistance (mmHg/L/min)

    Time frame: 3-6 hours

  34. Pulmonary Capillary Wedge Pressure (mmHg)

    Time frame: 3-6 hours

  35. Diastolic Pulmonary Arterial Pressure (mmHg)

    Time frame: 3-6 hours

  36. Systolic Pulmonary Artery Pressure (mmHg)

    Time frame: 3-6 hours

  37. Right Atrium Pressure (mmHg)

    report measurement

    Time frame: 3-6 hours

  38. Aortic Pulsatility Index (API)

    calculated measurement

    Time frame: 3-6 hours

  39. Cardiac Power Input (W/m²)

    Time frame: 3-6 hours

  40. Cardiac Power Output (Watts)

    Time frame: 3-6 hours

  41. Stroke Volume (mL)

    Time frame: 3-6 hours

  42. Cardiac Index (L/min/m²)

    Time frame: 3-6 hours

  43. Cardiac Output (L/min)

    Time frame: 3-6 hours

  44. Pulmonary Artery Oxygen Saturation (%)

    Time frame: 3-6 hours

  45. Heart Rhythm

    Normal Sinus Rhythm, Atrial Fibrillation, Atrial Flutter, Ventricular Fibrillation, Ventricular Tachycardia, Sinus Bradycardia, Sinus Tachycardia, other

    Time frame: 3-6 hours

  46. Heart Rate (beats per minute)

    Time frame: 3-6 hours

  47. Mean Arterial Pressure (mmHg)

    Time frame: 3-6 hours

  48. Diastolic Blood Pressure (mmHg)

    Time frame: 3-6 hours

  49. Systolic Blood Pressure (mmHg)

    Time frame: 3-6 hours

  50. Pulmonary Artery Compliance (mmHg)

    Time frame: 30 minutes

  51. Right Ventricular Stroke Work Index (g·m-²·beat-¹)

    Time frame: 30 minutes

  52. Pulmonary Artery Pulsatility Index (PAPi)

    calculated measurement

    Time frame: 30 minutes

  53. Pulmonary Vascular Resistance (dynes/cm⁵)

    Time frame: 30 minutes

  54. Systemic Vascular Resistance (mmHg/L/min)

    Time frame: 30 minutes

  55. Pulmonary Capillary Wedge Pressure (mmHg)

    Time frame: 30 minutes

  56. Diastolic Pulmonary Arterial Pressure (mmHg)

    Time frame: 30 minutes

  57. Systolic Pulmonary Artery Pressure (mmHg)

    Time frame: 30 minutes

  58. Right Atrium Pressure (mmHg)

    report measurement

    Time frame: 30 minutes

  59. Aortic Pulsatility Index (API)

    calculated measurement

    Time frame: 30 minutes

  60. Cardiac Power Input (W/m²)

    Time frame: 30 minutes

  61. Stroke Volume (mL)

    Time frame: 30 minutes

  62. Cardiac Power Output (Watts)

    Time frame: 30 minutes

  63. Cardiac Index (L/min/m²)

    Time frame: 30 minutes

  64. Cardiac Output (L/min)

    Time frame: 30 minutes

  65. Pulmonary Artery Oxygen Saturation (%)

    Time frame: 30 minutes

  66. Heart Rhythm

    Normal Sinus Rhythm, Atrial Fibrillation, Atrial Flutter, Ventricular Fibrillation, Ventricular Tachycardia, Sinus Bradycardia, Sinus Tachycardia, other

    Time frame: 30 minutes

  67. Heart Rate (beats per minute)

    Time frame: 30 minutes

  68. Mean Arterial Pressure (mmHg)

    Time frame: 30 minutes

  69. Diastolic Blood Pressure (mmHg)

    Time frame: 30 minutes

  70. Ultimate Disposition

    Heart recovery with discharge (alive)

    Time frame: Longitudinal Follow-Up (approximately 3 months)

  71. Ultimate Disposition

    Left Ventricular Assist Device (LVAD)

    Time frame: Longitudinal Follow-Up (approximately 3 months)

  72. Ultimate Disposition

    Transplant

    Time frame: Longitudinal Follow-Up (approximately 3 months)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 11 months is below that.

Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Feb 11, 2026
StartActual
Jan 27, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07402018
Responsible party
Matthew Delfiner (Principal Investigator: Matthew S Delfiner DO, MS, Thomas Jefferson University) — Principal investigator
First posted
Feb 11, 2026
Start date
Jan 27, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 11, 2026

Study contacts

Elizabeth R Westburg, MS
Contact
elizabeth.westburg@jefferson.edu
215-955-2050
Matthew S Delfiner, DO, MS
Contact
215-955-2050
Matthew S Delfiner, DO, MS
principal investigator · Thomas Jefferson University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion